While many are discouraged by CAR T-cell therapy’s lack of success treating solid tumors, Cell BT sees a bright light of hope.
Our solid tumor programs are designed to overcome the main obstacles to CAR T success:
Our lead hematological program is based on a powerful combination of a unique platform and a novel target. Cell BT is leading IND-enabling studies for phase one clinical trial readiness.
We expect human trials to confirm this to be a major advance that offers:
*huLym-1-B-DAP showed rapid onset and persistence at a 60% lower dose
We’re seeing new ways CAR T-cells can engage the patient’s own immune system to synergistically target and destroy tumors. This immune system interaction or “upgrade” confers immunological memory to prevent tumors from returning permanently. This synergy also can enhance tumor recognition which is important for preventing the outgrowth and spread of antigen negative lesions.
Cell BT is meeting one of the greatest challenges facing broad CAR T availability: cost.
A highly effective therapy with an astronomical price tag is not a sustainable, scalable model. At Cell BT, we are developing a method to be used universally in combination with any CAR T therapy to reduce cytokine side effects. This will reduce the need for patient monitoring and allow treatment to take place on an outpatient basis, dramatically lowering cost.
Co-stimulatory and signaling domains for hematological malignancies and solid tumors.
Novel technology to improve the efficacy and lower the toxicity of CAR T-cell therapy of deep-seated solid tumors.
Universal target for treating solid tumors.
Universal method for reducing cytokine secretion by CAR T-cells, the known cause of adverse events.
Treatment to induce CAR T-cell memory.